Physician profile
Joanne Piaggio
NPI 1194372086
$2,950.05
in general payments reported to CMS, 2019-2025
19 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.78 · 2022: $101 · 2023: $326 · 2024: $845 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476.63 | 2021-2025 | |
| Tris Pharma INC | $405.40 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Otsuka America Pharmaceutical, INC. | $385.43 | 2021-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $298.15 | 2023-2025 | Auvelity |
| Lundbeck LLC | $292.34 | 2023-2025 | Rexulti |
| Bausch Health US, LLC | $162.35 | 2024-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $147.89 | 2022-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $137.57 | 2023-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $129.28 | 2024-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.45 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $114.07 | 2024-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $93.90 | 2023-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $47.27 | 2025 | Fanapt |
| Almatica Pharma LLC | $45.43 | 2024-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $32.24 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $24.21 | 2023 | Azstarys |
| Noven Therapeutics, LLC | $14.97 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $13.73 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $12.74 | 2023 | Lamotrigine, Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Piaggio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.